Navigation Links
Actavis Receives Approval of Generic Wellbutrin XL(R) 300mg in the U.S.
Date:8/18/2008

MORRISTOWN, N.J., Aug. 18 /PRNewswire/ -- Actavis Group, the international generic pharmaceuticals company, today announced that it has received approval from the U.S. Food & Drug Administration to market Bupropion Hydrochloride extended-release tablets (XL) 300mg. Distribution of the product will commence immediately.

Bupropion Hydrochloride extended-release tablets (XL), available in 300mg strength, are the generic equivalent of Wellbutrin XL(R) for the treatment of major depressive disorder. Annual US sales of brand and generic Wellbutrin XL(R) 300mg were US$581 million for the 12 months ending June 2008 according to IMS Health data.

Commenting on the new approval, Douglas Boothe, Chief Executive Officer of Actavis, Inc. said:

"Bupropion XL compliments our existing Buproprion SR offerings and expands the dosage options for our customers and patients. This approval also highlights Actavis Group's focus and expertise in bringing complex controlled-release technologies to the marketplace."

About Actavis

Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. With headquarters in Iceland, Actavis has operations in 40 countries, with 11,000 employees. The United States is the company's single largest market. Actavis' U.S. operations are located in New Jersey, Maryland, North Carolina and Florida.

More information about Actavis in the United States can be found at http://www.actavis.us.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause ac
'/>"/>

SOURCE Actavis Group
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Harvard Business School Publishes a Case Study on Robert Wessman and Actavis
2. Actavis Extends Portfolio With Four New Products in the U.S.
3. Actavis Confirms its Patent Challenge of Kings Avinza(R)
4. Actavis Launches Amlodipine Tablets in the U.S.
5. Actavis Launches Carvedilol Tablets in the U.S.
6. New probe to detect skin cancer receives more funding for clinical trials
7. NUCRYST Receives Deficiency Notice from NASDAQ
8. Dr. Ajrawats Air-Pulse Autonomic Meditation Therapy, a Revolutionary, Scientific, Meditation Therapy, Receives Patent Trademark
9. PathNet Esoteric Laboratory Institute Main Laboratory Receives Accreditation From College of American Pathologists
10. Duska Therapeutics Receives Comments From FDA on Phase 3 ATPace(TM) Protocol Synopsis
11. Morris Animal Foundation Receives $1 Million Donation From Hills for Cat Health Research - Cat Lovers Have Reason to Celebrate

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...ate as a division of Xybion Corporation. , ...r 1, 2009 -- Xybion Corporation announced today th...ng assets of Quebec City based Amadeus Solutions, ...ce, risk, compliance and quality management softwa...e management organization headquartered in Montrea...
(Date:12/1/2009)..., MD was elected to the Stemedica Cell Technologie...rs at the Company’s November 20th Board Meet..., 2009 -- Anthony M. Marlon, MD was elected to the...dica”) Board of Directors at the Company&rsq...hD, Executive Chairman for Stemedica made the anno...
(Date:12/1/2009)...-- What many spa clients have thought for years, a...claimed in the 2009 AsiaSpa Awards: Thailand is in...ons including "Asian Spa Capital of the Year", Tha...Spa Awards, presented by AsiaSpa magazine, the reg..., during a glittering ceremony recently in Hong Ko...
(Date:12/1/2009)...lastography can help differentiate between cancero...y presented today at the annual meeting of the Rad...gh-frequency ultrasound with elastography has the ... diagnosis," said lead author Eliot L. Siegel, M.D... the University of Maryland School of Medicine (UM...
(Date:12/1/2009)...n-related injuries and deaths in the U.S. finds th...ospitals with aviation-related injuries annually, ...study, conducted by researchers from the Johns Hop...r Injury Research and Policy and Columbia Universi...tients were occupants of civilian, noncommercial p...
Breaking Medicine News(10 mins):Health News:Xybion Acquires Amadeus, a Leader in Governance, Risk, Compliance and Quality Management (GRC) Solutions 2Health News:Xybion Acquires Amadeus, a Leader in Governance, Risk, Compliance and Quality Management (GRC) Solutions 3Health News:Prominent Health Care Executive Joins Stemedica Board Of Directors 2Health News:Prominent Health Care Executive Joins Stemedica Board Of Directors 3Health News:Thailand - Spa Capital of Asia by Karen Emmons 2Health News:Thailand - Spa Capital of Asia by Karen Emmons 3Health News:Thailand - Spa Capital of Asia by Karen Emmons 4Health News:Thailand - Spa Capital of Asia by Karen Emmons 5Health News:Special ultrasound accurately identifies skin cancer 2Health News:More than 1,000 patients in US admitted annually for aviation-related injuries 2
... in vitro patients, fewer multiple pregnancies , ...rchers say DNA tests may be able to tell doctors w...F) are most likely to result in the births of heal...al multiple pregnancies in their IVF patients. , A...
...its five cities in one ...ounder and primary,teacher of the Institute for In... school, is hosting a public lecture series in fiv...he,challenges and opportunities that exist in Amer...
...erna Zentaris Inc.,(NASDAQ: AEZS ; TSX: AEZ), a g...ne therapy and oncology, today reported dosing has...ase 3 program with cetrorelix in benign,prostatic ...ndidate.,This 500-patient safety trial is the thir...
... /PRNewswire-FirstCall/,-- HeartWare Limited (ASX:... an investor presentation at the Seventh Annual JM...12:30 p.m. ET) on Wednesday, May 21, 2008. The,con... via a link provided at http://www.heartware.com ...
...ors has fine-tuned the dosage and timing for admin... (tPA) to patients with strokes caused by bleeding... week at the European Stroke Conference in Nice, F...s usually an 80 percent death rate in patients wit...
...d self esteem, SAUSALITO, Calif., May 14 When Pe...t a young woman was afraid to go to school,because...she took action.,Peggy donated two of her custom-m...y to pay for it., Brittany began losing her hair ...
Other Medicine News:Health News:DNA Fingerprinting Could ID Viable Embryos 2Health News:Institute for Integrative Nutrition Begins Road Tour 2Health News:AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 2Health News:AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 3Health News:AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 4Health News:AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 5Health News:HeartWare to Present at Seventh Annual JMP Securities Research Conference 2Health News:Researchers fine-tune clot-busting treatment for bleeding in brain 2Health News:Teen Girl Loses Hair But Gains Support 2
(Date:11/30/2009)...Newswire/ -- Microban International, Ltd., the glo...ction, is pleased to announce their exclusive Nort...gest U.S. manufacturer and distributor of ceramic ...g two new lines of ceramic tile with OutStand Tech...ng silver based technology, in order to create a l...
(Date:11/30/2009)...swire-FirstCall/ -- Covance Inc. (NYSE: CVD ) to...ffray 21st Annual Health Care Conference on Wednes...s may access a live webcast of the presentation at...load any necessary software, please log on 10 minu...nceton, New Jersey, is one of the world,s largest ...
(Date:11/30/2009)...wire/ -- Reportlinker.com announces that a new mar... ,, Cardiac Defibrillators - A Worldwide Marke...ker.com/p0164315/Cardiac-Defibrillators---A-Worldw...vascular disease (CVD) is one of the foremost caus...ivors are prone to arrhythmic disorders, calling t...
Breaking Medicine Technology:Dal-Tile Corp. Launches Two New Lines of Ceramic Tile with Microban(R) Silver Antimicrobial Technology 2Reportlinker Adds Cardiac Defibrillators - A Worldwide Market Intelligence Report 2Reportlinker Adds Cardiac Defibrillators - A Worldwide Market Intelligence Report 3Reportlinker Adds Cardiac Defibrillators - A Worldwide Market Intelligence Report 4Reportlinker Adds Cardiac Defibrillators - A Worldwide Market Intelligence Report 5Reportlinker Adds Cardiac Defibrillators - A Worldwide Market Intelligence Report 6Reportlinker Adds Cardiac Defibrillators - A Worldwide Market Intelligence Report 7Reportlinker Adds Cardiac Defibrillators - A Worldwide Market Intelligence Report 8Pennsylvania Governor Signs Four Health Care Bills That Will Reduce Costs Improve Access and Quality 48537 1Pennsylvania Governor Signs Four Health Care Bills That Will Reduce Costs Improve Access and Quality 48537 2Pennsylvania Governor Signs Four Health Care Bills That Will Reduce Costs Improve Access and Quality 48537 3Pennsylvania Governor Signs Four Health Care Bills That Will Reduce Costs Improve Access and Quality 48537 4Pennsylvania Governor Signs Four Health Care Bills That Will Reduce Costs Improve Access and Quality 48537 5State to Invest 2411 1 Million in Expansion of Doylestown Hospital 48532 1State to Invest 2411 1 Million in Expansion of Doylestown Hospital 48532 2Ovarian Cancer Breakthrough Heralds New Era of Treatment 48527 1Ovarian Cancer Breakthrough Heralds New Era of Treatment 48527 2
...E)--Mar 26, 2007 - CombinatoRx,Incorporated (NASD... phase 2 clinical trial studying CRx-139 (a synerg...depressant paroxetine),and 3mg prednisolone alone,...trial served two important purposes. One purpose w...alone (a very low dose),in RA and to contrast this...
...--Mar 27, 2007 - Inotek,Pharmaceuticals Corporatio...se 2 clinical data demonstrating the safety of INO...reventative agent for,cardiac reperfusion injury. ...elevated myocardial infarction (STEMI) undergoing,...esentation was,made in a poster session at the Ame...
Other Medicine Technology:CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 2CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 3CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 4CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 5CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 6Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 2Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 3Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 4
11.50mm diameter Corneal Trephine Blades
9.25mm diameter Corneal Trephine Blades
8.50mm diameter Corneal Trephine Blades
8.00mm diameter Corneal Trephine Blades
Medicine Products: